Merck & Company, Inc. · NYSE:MRK
Merck & — ASCO Investor Event 2023
39 slides from Merck &'s conference presentation, Jun 5, 2023
Slide 1: ASCO Investor Event
PRESENT ASCO Investor Event June 5, 2023
Slide 2: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These state
Slide 3: Opening Remarks
Opening Remarks Dr. Dean Li President, Merck Research Laboratories
Slide 4: Agenda
Agenda Dr. Dean Li President, Merck Research Laboratories Opening Remarks | Dr. Dean Li Dr. Eliav Barr Strategy & Progress | Dr. Eliav Barr SVP, Head of Global Clinical Development & Chief Medical Officer Earlier Stage Lung Cancer | Dr. Gregory Lubiniecki Dr. Gregory Lubiniecki VP, Late Oncology Sel
Slide 5: Strategy & Progress
Strategy & Progress Dr. Eliav Barr SVP, Head of Global Clinical Development & Chief Medical Officer
Slide 6: Shaping the future of oncology with robust portfolio and pipeline
Shaping the future of oncology with robust portfolio and pipeline Immuno-oncology Tissue Targeting Precision Molecular Targeting Boost anti-tumor immune responses Increase cancer cell sensitivity Impact pathways that can drive with ADCs and immune-engagers cancer growth 4 5 favezelimab/pembro zilove
Slide 7: Structured process for advancing novel approaches to treating cancer and preventing certain HPV-related cancers
Structured process for advancing novel approaches to treating cancer and preventing certain HPV-related cancers Extend Prevention Development pathway to earlier stages of disease of certain for novel oncology HPV-related cancers mechanisms V9406 Expand • Establish beachhead as a & Deepen monotherapy
Slide 8: Multifaceted pipeline in late stages of cancer comprised of diverse agents targeting multiple tumor types
Multifaceted pipeline in late stages of cancer1 comprised of diverse agents targeting multiple tumor types Lung 4 Head & Neck4 3 MK-28702,5 Breast Broad pipeline vibostolimab 3 4 of novel oncology Genitourinary mechanisms 4 MK-28702,5 in Phase 3 across 3 multiple tumor types MK-56842,6 quavonlimab G
Slide 9: Extensive ongoing clinical development program for earlier stages of cancer
Extensive ongoing clinical development program for earlier stages of cancer1 Esophageal Head & Neck KN-975 KN-689 Lung Breast KN-091 KV-006 KL-012 KN-522 KN-242 KN-671 KN-867 KL-013 OLYMPIA KN-756 Approximately Liver Gastric 28,000 patients2 KN-937 LEAP-012 KN-585 in >25 active Phase 3 trials3 Renal
Slide 10: Subcutaneous therapies intended to deliver several important benefits across key stakeholders
Subcutaneous therapies intended to deliver several important benefits across key stakeholders Subcutaneous program Potential benefits to stakeholders MK-3475A: pembrolizumab + hyaluronidase Patients • Prioritizing coformulation based on potential • Increased access, time savings and may improve psyc
Slide 11: Seeking to identify optimal treatment options for patients
Seeking to identify optimal treatment options for patients Advancements in precision medicine are helping Select oncogenes, tumor suppressor genes to redefine how cancer is classified and treated and genomic alterations • Merck has 20 approved biomarker-driven VEGF indications, across products to he
Slide 12: Earlier Stage Lung Cancer
Earlier Stage Lung Cancer Dr. Gregory Lubiniecki VP, Late Oncology Development
Slide 13: Broad Phase 3 development program in earlier stages of lung cancer
Broad Phase 3 development program in earlier stages of lung cancer KEYNOTE- KEYNOTE- KEYNOTE- KEYLYNK- KEYLYNK- KEYVIBE- 091 671 867 012 013 006 Neoadjuvant / Locally Locally Locally Adjuvant Adjuvant Setting Resectable Adjuvant Inoperable Advanced Advanced Advanced Resectable Unresectable Unresecta
Slide 14: Compelling KEYNOTE-671 interim results add to evidence of KEYTRUDA's impact in earlier stage NSCLC
Compelling KEYNOTE-671 interim results add to evidence of KEYTRUDA's impact on patients with earlier stages of NSCLC Event-free survival Overall survival Exploratory analysis of EFS by pCR status +XX% YOY a. Significance boundary not met at IA1 KEYTRUDA plus chemotherapy before Favorable trend in OS
Slide 15: Select Late-Phase Programs
Select Late-Phase Programs Dr. Marjorie Green SVP, Head of Late Oncology Development
Slide 16: Four novel mechanisms beginning registrational studies in 2023
Four novel mechanisms beginning registrational studies in 2023 Immuno-oncology Tissue Targeting Precision Molecular Targeting Boost anti-tumor immune responses Increase cancer cell sensitivity Impact pathways that can drive with ADCs and immune-engagers cancer growth 4 5 favezelimab/pembro ziloverta
Slide 17: Expanded collaboration with Kelun Biotech accelerates expansive ADC development program
Expanded collaboration with Kelun Biotech accelerates expansive ADC development program Components of ADCs: antibody, linker, drug / payload Multiple ADC candidates across phases of development MK-2870 (anti-TROP2 ADC) Areas of study: TNBC, NSCLC and other advanced solid tumors 2 6 undisclosed ADCs
Slide 18: Promising Phase 1/2 data for MK-2870 demonstrates potential in NSCLC
Promising Phase 1/2 data for MK-2870 demonstrates potential in NSCLC Best change from baseline in sum of target lesions • MK-2870 demonstrated encouraging anti-tumor activity in patients with relapsed or refractory locally advanced or metastatic NSCLC − Objective response rate of 44% − Median durati
Slide 19: Encouraging data for adjuvant use of V940 (mRNA-4157) with pembrolizumab in stage III/IV melanoma
Encouraging data for adjuvant use of V940 (mRNA-4157) in combination with pembrolizumab in stage III/IV melanoma1 Distant metastasis-free survival • V940 (mRNA-4157) and pembrolizumab reduced the risk of distant metastasis or death by 65% vs pembrolizumab alone in patients with stage III/IV melanoma
Slide 20: MK-5684 (CYP11A1i) provides promising evidence of anti-tumor activity in patients with mCRPC
MK-5684 (CYP11A1i) provides promising evidence of anti-tumor activity in patients with mCRPC Mechanism of action Clinical data and development program • MK-5684 is an oral nonsteroidal CYP11A1 inhibitor that works • MK-5684 provides promising evidence of anti-tumor activity by suppressing the produc
Slide 21: Bomedemstat is a potent, irreversible inhibitor of LSD1 with potential to be disease modifying
Bomedemstat is a potent, irreversible inhibitor of LSD1 with potential to be disease modifying in myeloproliferative diseases Mechanism of action Clinical data and development program • LSD1 may regulate the proliferation of hematopoietic • Phase 2 results from Essential Thrombocythemia trial demons
Slide 22: Commercial Update
Commercial Update Chirfi Guindo Chief Marketing Officer, Human Health
Slide 23: Driving patient benefits and global growth across a broad portfolio of commercial therapies
Driving patient benefits and global growth across a broad portfolio of commercial therapies Foundational cancer Market-leading TKI with multiple ~1.9 million patients have been treated with treatment PARPi approved indications commercially available medicines1 48 approved indications Highly-selectiv
Slide 24: Advancing and expanding a broad program in earlier stages of cancer
Advancing and expanding a broad program in earlier stages of cancer 2018–2022 2023–2025 2026+ KN-054 KN-564 KN-091 KN-866 KN-689 KN-242 KN-B15 LITESPARK-022 Melanoma RCC NSCLC MIBC HNSCC TNBC MIBC RCC APPROVED APPROVED APPROVED KN-057 KN-716 KN-671 KN-123 KN-630 KN-756 KN-975 KEYLYNK-012 NMIBC
Slide 25: Strong launches across recent indications in earlier stages of cancer
Strong launches across recent indications in earlier stages of cancer KN-522: TNBC KN-716: Melanoma KN-564: RCC • First and only anti-PD-1 regimen to • First and only anti-PD-1 adjuvant • First and only immunotherapy to demonstrate pCR and EFS in earlier treatment option approved demonstrate efficac
Slide 26: KEYTRUDA based regimens provide opportunity to improve outcomes across earlier stage and advanced NSCLC
KEYTRUDA based regimens provide opportunity to significantly improve clinical outcomes across earlier stage and advanced NSCLC Extending leadership in NSCLC Providing treatment options for patients • KN-671 and KN-091 results build on wealth of data in NSCLC • Upon approval of KN-671, and with the r
Slide 27: Multiple growth drivers that will enable sustained leadership in oncology
Multiple growth drivers that will enable sustained leadership in oncology • Expected to drive >50% of KEYTRUDA’s annual growth through 2025 Moving into earlier stage • Expected to represent ~25% of global KEYTRUDA sales in 2025 and increase as a % of total cancers sales thereafter • Subcutaneous cof
Slide 28: Closing Remarks
Closing Remarks Dr. Dean Li President, Merck Research Laboratories
Slide 29: Structured process for advancing novel approaches to treating cancer and preventing certain HPV-related cancers
Structured process for advancing novel approaches to treating cancer and preventing certain HPV-related cancers Extend Prevention Development pathway to earlier stages of disease of certain for novel oncology HPV-related cancers mechanisms V9406 Expand • Establish beachhead as a & Deepen monotherapy
Slide 30: Q&A
Q&A Dr. Dean Li Dr. Eliav Barr Dr. Marjorie Green Chirfi Guindo President, SVP, Head of Global SVP, Head of Late Chief Marketing Officer, Merck Research Clinical Development & Oncology Development Human Health Laboratories Chief Medical Officer Dr. Gregory Lubiniecki Dr. Scot Ebbinghaus Dr. Gursel A
Slide 31: Appendix
INVENTING FOR LIFE Appendix
Slide 32: Acronyms
Acronyms ADC = Antibody-drug conjugate IO = Immuno-oncology PCD = Primary completion date BTK = Bruton’s tyrosine kinase IV = Intravenously pCR = Pathological complete response CI = Confidence Interval KRAS = Kirsten rat sarcoma viral oncogene homolog PDUFA = Prescription Drug User Fee Act cSCC = Cu
Slide 33: Dean Li, M.D., Ph.D.
Dean Li, M.D., Ph.D. President, Merck Research Laboratories Dr. Dean Li serves as executive vice president and president of Merck Research Laboratories. He leads the company’s worldwide human vaccines and therapeutics research and development organization. Since joining Merck in 2017, Dean has held
Slide 34: Eliav Barr, M.D.
Eliav Barr, M.D. Senior Vice President Head of Global Clinical Development, Chief Medical Officer Dr. Eliav Barr is senior vice president and head of Global Clinical Development and Chief Medical Officer at Merck Research Laboratories. He leads all late-stage clinical development for Merck’s human h
Slide 35: Marjorie Green, M.D.
Marjorie Green, M.D. Senior Vice President Head of Late-Stage Oncology, Global Clinical Development Dr. Marjorie Green is senior vice president and head of late-stage oncology at Merck Research Laboratories. She leads all late-stage clinical development programs for oncology. Marjorie joins Merck fr
Slide 36: Chirfi Guindo
Chirfi Guindo Chief Marketing Officer, Human Health Chirfi Guindo is chief marketing officer for Merck. He is responsible for leading the development and implementation of the company’s long-term strategy for the human health portfolio spanning oncology, vaccines, pharmaceutical and pipeline product
Slide 37: Gregory Lubiniecki, M.D.
Gregory Lubiniecki, M.D. Vice President, Late Oncology Development Dr. Gregory Michael Lubiniecki is Vice President and Therapeutic Area Head at Merck Research Laboratories, where he has been employed for over 15 years in oncology clinical research. Gregory has worked on many clinical trials ranging
Slide 38: Scot Ebbinghaus, M.D.
Scot Ebbinghaus, M.D. Vice President, Late Oncology Development Dr. Scot Ebbinghaus joined Merck Research Laboratories Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the develo
Slide 39: Gursel Aktan, M.D., Ph.D.
Gursel Aktan, M.D., Ph.D. Vice President, Late Oncology Development Dr. Gursel Aktan joined Merck in August 2014 as the Breast Product Development Team Lead where she developed a comprehensive Breast Clinical Development program for early and late stage Breast Cancer. She was promoted to Section Hea